An Introduction to Allergic Diseases
The incidence of respiratory allergies is increasing, particularly in industrialized areas. Allergic inflammation can occur in both the upper and lower airways, and can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying respiratory allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Dupilumab—A Potential New Biologic for Chronic Rhinosinusitis with Nasal Polyps
US Respiratory & Pulmonary Diseases. 2020;5(1):Epub ahead of publication
Chronic rhinosinusitis (CRS) is a clinical syndrome defined by symptomatic inflammation of the paranasal sinuses and nasal cavity for at least 12 weeks in duration. Historically, CRS has been classified into 2 subgroups, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Those with CRSwNP have a more significant burden of disease and poor […]
Call for Submissions 2018
US Respiratory & Pulmonary Diseases, 2017;2(1):Epub ahead of print
US Respiratory & Pulmonary Diseases invites colleagues in the respiratory care and pulmonary disease community to contribute articles for the 2018 edition. US Respiratory & Pulmonary Diseases aims to provide practicing physicians, and related healthcare professionals in the field, with concise and timely articles that provide practical advice and help them in their day-to-day clinical […]
EAACI 2017 – Enrico Heffler Interview – Part 2
EAACI Asthma Section Member, Dr Enrico Heffler, considers the biggest recent breakthroughs in the use of biologic therapies in allergies and what other molecules may hold promise as biomarkers in allergy and asthma. Part 2 of 2. View Part 1 here. Speaker disclosures: nothing to disclose. Filmed at the European Academy of Allergy and Clinical […]
EAACI 2017 – Enrico Heffler Interview – Part 1
EAACI Asthma Section Member, Dr Enrico Heffler, discusses unmet needs in allergy research, challenges in stratifying different allergy phenotypes and potential of microRNAs as biomarkers in asthma. Part 1 of 2. View Part 2 here. Speaker disclosures: nothing to disclose. Filmed at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Helsinki, Finland, […]
How is climate change affecting allergies and asthma?
Learn how is climate change affecting allergies and asthma.
Sublingual Immunotherapy for Respiratory Allergy
European Respiratory and Pulmonary Diseases, 2015;1(1):25–6 DOI: //doi.org/10.17925/ERPD.2015.01.01.25
In the late 1980s, sublingual allergen immunotherapy (SLIT) was proposed as an ‘alternative’ to subcutaneous allergen immunotherapy (SCIT).1,2 The main aim was to reduce systemic reactions and the risk of anaphylaxis, which were frequently associated with SCIT and also to increase the number of patients receiving allergen immunotherapy by facilitating its regular use at home. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!